Lilly boosts ‘in vivo’ cell therapy capabilities with Kelonia buyout
Summary
Worth up to $7 billion, Lilly’s second recent acquisition of a company in the space is centered around a cell therapy that’s currently in early-stage testin...
Description
Worth up to $7 billion, Lilly’s second recent acquisition of a company in the space is centered around a cell therapy that’s currently in early-stage testin...
Original reporting
AFBytes is a read-only aggregator. Use the original source for full context and complete reporting.
Open original source